SUPERNUS PHARMACEUTICALS INC (SUPN) Fundamental Analysis & Valuation

NASDAQ:SUPN • US8684591089

Current stock price

48.465 USD
-0.08 (-0.18%)
Last:

This SUPN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. SUPN Profitability Analysis

1.1 Basic Checks

  • SUPN had positive earnings in the past year.
  • SUPN had a positive operating cash flow in the past year.
  • Of the past 5 years SUPN 4 years were profitable.
  • In the past 5 years SUPN always reported a positive cash flow from operatings.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

1.2 Ratios

  • SUPN has a Return On Assets of -2.65%. This is in the better half of the industry: SUPN outperforms 74.87% of its industry peers.
  • With a decent Return On Equity value of -3.63%, SUPN is doing good in the industry, outperforming 78.01% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 0.76%, SUPN is in the better half of the industry, outperforming 78.53% of the companies in the same industry.
  • SUPN had an Average Return On Invested Capital over the past 3 years of 2.78%. This is significantly below the industry average of 13.10%.
Industry RankSector Rank
ROA -2.65%
ROE -3.63%
ROIC 0.76%
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)2.78%
ROIC(5y)3.35%
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • The Operating Margin of SUPN (1.55%) is better than 78.53% of its industry peers.
  • SUPN's Operating Margin has declined in the last couple of years.
  • SUPN has a better Gross Margin (89.89%) than 92.67% of its industry peers.
  • In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
Industry RankSector Rank
OM 1.55%
PM (TTM) N/A
GM 89.89%
OM growth 3Y-36.8%
OM growth 5Y-45.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.12%
GM growth 5Y0%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SUPN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
  • SUPN has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, SUPN has more shares outstanding
  • SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • SUPN has an Altman-Z score of 5.56. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
  • SUPN's Altman-Z score of 5.56 is fine compared to the rest of the industry. SUPN outperforms 75.92% of its industry peers.
  • There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.56
ROIC/WACC0.08
WACC9.72%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 1.90 indicates that SUPN should not have too much problems paying its short term obligations.
  • SUPN has a worse Current ratio (1.90) than 65.97% of its industry peers.
  • A Quick Ratio of 1.66 indicates that SUPN should not have too much problems paying its short term obligations.
  • SUPN has a Quick ratio of 1.66. This is in the lower half of the industry: SUPN underperforms 63.87% of its industry peers.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.66
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. SUPN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 8.14% over the past year.
  • The Earnings Per Share has been growing slightly by 6.21% on average over the past years.
  • The Revenue has grown by 8.63% in the past year. This is quite good.
  • The Revenue has been growing slightly by 6.68% on average over the past years.
EPS 1Y (TTM)8.14%
EPS 3Y45.76%
EPS 5Y6.21%
EPS Q2Q%12%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%

3.2 Future

  • SUPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.52% yearly.
  • SUPN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.29% yearly.
EPS Next Y-38.5%
EPS Next 2Y23.69%
EPS Next 3Y18.42%
EPS Next 5Y17.52%
Revenue Next Year23.14%
Revenue Next 2Y21.12%
Revenue Next 3Y18.26%
Revenue Next 5Y14.29%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

5

4. SUPN Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 15.19, SUPN is valued correctly.
  • 86.39% of the companies in the same industry are more expensive than SUPN, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 26.54. SUPN is valued slightly cheaper when compared to this.
  • The Price/Forward Earnings ratio is 24.70, which indicates a rather expensive current valuation of SUPN.
  • Based on the Price/Forward Earnings ratio, SUPN is valued a bit cheaper than the industry average as 75.92% of the companies are valued more expensively.
  • SUPN is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.68, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 15.19
Fwd PE 24.7
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 80.10% of the companies in the same industry are more expensive than SUPN, based on the Enterprise Value to EBITDA ratio.
  • SUPN's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. SUPN is cheaper than 76.96% of the companies in the same industry.
Industry RankSector Rank
P/FCF 60.67
EV/EBITDA 22.45
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SUPN's earnings are expected to grow with 18.42% in the coming years.
PEG (NY)N/A
PEG (5Y)2.45
EPS Next 2Y23.69%
EPS Next 3Y18.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SUPN Dividend Analysis

5.1 Amount

  • SUPN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SUPN Fundamentals: All Metrics, Ratios and Statistics

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (4/30/2026, 3:02:59 PM)

48.465

-0.08 (-0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength65.84
Industry Growth15.53
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners103.51%
Inst Owner Change1.57%
Ins Owners4.36%
Ins Owner Change1.57%
Market Cap2.79B
Revenue(TTM)718.95M
Net Income(TTM)-38.55M
Analysts83.33
Price Target64.43 (32.94%)
Short Float %8.6%
Short Ratio6.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)105.02%
Min EPS beat(2)67.83%
Max EPS beat(2)142.22%
EPS beat(4)4
Avg EPS beat(4)78.33%
Min EPS beat(4)15.55%
Max EPS beat(4)142.22%
EPS beat(8)7
Avg EPS beat(8)76.31%
EPS beat(12)10
Avg EPS beat(12)66.61%
EPS beat(16)11
Avg EPS beat(16)43.29%
Revenue beat(2)2
Avg Revenue beat(2)5.83%
Min Revenue beat(2)5.28%
Max Revenue beat(2)6.37%
Revenue beat(4)3
Avg Revenue beat(4)4.06%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)6.37%
Revenue beat(8)6
Avg Revenue beat(8)5.39%
Revenue beat(12)9
Avg Revenue beat(12)4.44%
Revenue beat(16)11
Avg Revenue beat(16)2.87%
PT rev (1m)2.99%
PT rev (3m)2.99%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-35.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-53.95%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)-0.83%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-0.47%
Valuation
Industry RankSector Rank
PE 15.19
Fwd PE 24.7
P/S 3.88
P/FCF 60.67
P/OCF 58.96
P/B 2.63
P/tB 7.6
EV/EBITDA 22.45
EPS(TTM)3.19
EY6.58%
EPS(NY)1.96
Fwd EY4.05%
FCF(TTM)0.8
FCFY1.65%
OCF(TTM)0.82
OCFY1.7%
SpS12.49
BVpS18.44
TBVpS6.38
PEG (NY)N/A
PEG (5Y)2.45
Graham Number36.3793 (-24.94%)
Profitability
Industry RankSector Rank
ROA -2.65%
ROE -3.63%
ROCE 1%
ROIC 0.76%
ROICexc 1.05%
ROICexgc 7.57%
OM 1.55%
PM (TTM) N/A
GM 89.89%
FCFM 6.4%
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)2.78%
ROIC(5y)3.35%
ROICexc(3y)4.57%
ROICexc(5y)5.05%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.69%
ROCE(5y)4.7%
ROICexgc growth 3Y-30.81%
ROICexgc growth 5Y-24.6%
ROICexc growth 3Y-31.42%
ROICexc growth 5Y-41%
OM growth 3Y-36.8%
OM growth 5Y-45.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.12%
GM growth 5Y0%
F-Score5
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1.46%
Cap/Sales 0.19%
Interest Coverage 250
Cash Conversion 46.07%
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.66
Altman-Z 5.56
F-Score5
WACC9.72%
ROIC/WACC0.08
Cap/Depr(3y)1%
Cap/Depr(5y)1.92%
Cap/Sales(3y)0.13%
Cap/Sales(5y)0.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.14%
EPS 3Y45.76%
EPS 5Y6.21%
EPS Q2Q%12%
EPS Next Y-38.5%
EPS Next 2Y23.69%
EPS Next 3Y18.42%
EPS Next 5Y17.52%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%
Revenue Next Year23.14%
Revenue Next 2Y21.12%
Revenue Next 3Y18.26%
Revenue Next 5Y14.29%
EBIT growth 1Y-87.66%
EBIT growth 3Y-35.2%
EBIT growth 5Y-41.44%
EBIT Next Year14.86%
EBIT Next 3Y40.14%
EBIT Next 5Y27.81%
FCF growth 1Y-73.14%
FCF growth 3Y-26.62%
FCF growth 5Y-19.37%
OCF growth 1Y-72.47%
OCF growth 3Y-26%
OCF growth 5Y-19.31%

SUPERNUS PHARMACEUTICALS INC / SUPN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to SUPN.


What is the valuation status for SUPN stock?

ChartMill assigns a valuation rating of 5 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.


How profitable is SUPERNUS PHARMACEUTICALS INC (SUPN) stock?

SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for SUPN stock?

The Price/Earnings (PE) ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 15.19 and the Price/Book (PB) ratio is 2.63.


How financially healthy is SUPERNUS PHARMACEUTICALS INC?

The financial health rating of SUPERNUS PHARMACEUTICALS INC (SUPN) is 6 / 10.